Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2010

View Archived Issues

In vivo data support clinical development of VX15/2503 for MS

OBA-19 offers neuroprotection in model of ischemic stroke

Firategrast suppresses onset of new lesions in relapsing-remitting MS

Telatinib shows promise in patients with cancer of the stomach or gastroesophageal junction

Phase II/III data support teriflunomide monotherapy for relapsing MS

New antagonists of transient receptor potential TRPA1 channel claimed

Theravance announces results from phase I/II TD-1211 studies

Quark Pharma begins phase I QPI-1007 trial for ocular neuroprotection

Risk of abnormal heart rhythm added to Invirase label

Depomed delivers prototype formulation of fixed-dose metformin/canagliflozin

Phase III trial of clofarabine/cytarabine combination in leukemia meets secondary endpoints

Biogen Idec and Genentech amend collaboration agreement on CD20-targeting antibodies

Trastuzumab approved by FDA for HER2-positive metastatic stomach cancer

BioMarin claims new benzoxazole derivatives for dystrophy and cachexia

Phase IIb trial of inhaled liposomal ciprofloxacin meets primary endpoint

Merck & Co. claims new P2X3 receptor antagonists

Enrollment suspended in ACT 5 trial of vernakalant hydrochloride

ACADIA claims new serotonin 5-HT2A receptor modulators

Phase III data presented on oral calcitonin in osteoarthritis

CHMP issues positive opinion on ranibizumab for DME-related vision impairment

PolyMedix plans phase II studies of PMX-60056

Flamel Technologies achieves milestone for extended release interferon beta-1a

Advaxis advances phase II ADXS11-001 trial in cervical dysplasia

FDA requests additional information in complete response letter on lorcaserin NDA

Phase II study of Intercell's IC-43 meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...